Results 21 to 30 of about 1,126 (138)

Effect of emicizumab-neutralizing antibodies on activated partial thromboplastin time–based clotting time test results in patients treated with emicizumab [PDF]

, 2023
Background: Emicizumab is a bispecific humanized monoclonal antibody that shortens the activated partial thromboplastin time (aPTT), making aPTT-based tests unreliable.
Novembrino, Cristina, Peyvandi, Flora, Boscolo-Anzoletti, Massimo, Shinohara, Sho, Galbiati, Eleonora   +4 more
core   +1 more source

Emicizumab in severe hemophilia A [PDF]

, 2021
Emicizumab is a recombinant, humanized, bispecific, asymmetric monoclonal antibody that bridges activated factor IX and factor X (FX) and leads to activation of FX, thus mimicking the hemostatic function of activated factor VIII (FVIIIa).
Windyga, Jerzy; Department of Disorders of Hemostasis and Internal Diseases and Department of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
core   +1 more source

Thromboelastography Profiles of Hemophilia A patients on Emicizumab [PDF]

, 2022
Emicizumab is a new monoclonal antibody developed to dtreat people with Hemophilia A, especially those with antibodies. However, breakthrough bleeding can still occur in patients taking Emicizumab.
VanZweden, Daniel J, Chitlur, Meera, Stadler, Charity J   +2 more
core   +1 more source

Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab. [PDF]

, 2020
INTRODUCTION Emicizumab (Hemlibra®, Hoffmann-La Roche, Switzerland) is now available for haemophilia A patients with or without factor VIII inhibitors.
Gerber, B., Hegemann, Inga, Korte, W., Kremer Hovinga, Johanna A, Johanna A. Kremer Hovinga, Kremer Hovinga, J.A., Manuela Albisetti, Angelillo-Scherrer, A., Wolfgang Korte, Walter A. Wuillemin, Kremer Hovinga, Johanna A., Wuillemin, W.A., Studt, J.D., Studt, Jan-Dirk, Alberio, Lorenzo, Alberio, L., Dimitrios A. Tsakiris, Casini, A., Angelillo-Scherrer, Anne, Lorenzo Alberio, Maria Martinez, Tsakiris, Dimitrios A, Anne Angelillo-Scherrer, Lars M. Asmis, Tsakiris, D.A., Pierre Fontana, Albisetti, Manuela, Asmis, L.M., Graf, Lukas, Angelillo, Anne, Lukas Graf, Albisetti, M., Gerber, Bernhard, Bernhard Gerber, Martinez, Maria, Casini, Alessandro, Alessandro Casini, Inga Hegemann, Graf, L., Jan-Dirk Studt, Hegemann, I., Fontana, P., Asmis, Lars M, Fontana, Pierre, Korte, Wolfgang, Martinez, M., Wuillemin, Walter A   +46 more
core   +2 more sources

Haemophilia A management with emicizumab: A survey of haematologists in the United States

, 2021
Emicizumab is a bispecific monoclonal antibody approved in the United States (US) for the treatment of people with haemophilia A (PwHA) with or without factor VIII (FVIII) inhibitors.
Poulos Kathleen, Ko Richard H., Patel Anisha M., Wong Gabriel, Bernard Janet, Raimundo Karina, Powers Janet, Owens Wendy E., Gabriel Wong, Kathleen Poulos, Wendy E. Owens, Richard H. Ko, Karina Raimundo, Anisha M. Patel, Janet Bernard, Janet Powers   +15 more
core   +1 more source

Emicizumab: the hemophilia A game changer

Haematologica, 2023
In hemophilia, the unmet needs regarding adherence to prophylaxis and lack of effective longterm prophylaxis regimens, especially in patients with inhibitors, led to the production of emicizumab, the first non-factor medicine for subcutaneous administration in patients with severe and moderate hemophilia A with or without factor VIII inhibitors.
Pedro E. Alcedo Andrade, Pier Mannuccio Mannucci, Craig M. Kessler   +2 more
openaire   +3 more sources

The impact of higher concentrations of FIX and FX on determination of emicizumab plasma level.

, 2022
FVIII-deficient plasma was spiked with FIX (A) or FX (B) to reach 100%, 150% and 200% of normal plasma levels in molarity. Then samples were spiked with emicizumab (● indicates 100 μg/ml emicizumab; ■ 10 μg/ml emicizumab and ▲ without emicizumab).
Johannes Oldenburg (138185), Jens Müller (263387), Bernd Pötzsch (615446), Nasim Shahidi Hamedani (13046936)   +3 more
core   +1 more source

Emicizumab-kxwh: First Global Approval

, 2018
Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding.Conflicts of interest: Lesley Scott and Esther Kim are salaried employee of Adis/Springer, are responsible for the article content and ...
Lesley J Scott (4995230), Esther S. Kim, Lesley J. Scott, Esther S Kim (5082863)   +3 more
core   +1 more source

Pharmacodynamics Monitoring of Emicizumab in Patients with Hemophilia A

, 2023
Background: Emicizumab is a bispecific antibody mimicking coagulation factor VIII (FVIII) employed to treat patients with hemophilia A (PwHA) regardless of FVIII inhibitor status.
Batista Mesquita Sauvage, Ana Patricia, Rita Marchi Cappelletti, Durual, Stéphane, Gomez, Francisco J, Aliotta, Alessandro, Zermatten, M.G., Francisco J. Gomez, Debora Bertaggia Calderara, Alberio, Lorenzo, Ana Patricia Batista Mesquita Sauvage, Durual, S., Alberio, L., Bertaggia Calderara, D., Casini, A., Lorenzo Alberio, Bertaggia Calderara, Debora, Aliotta, A., Maxime G. Zermatten, Stéphane Durual, Batista Mesquita Sauvage, A.P., Zermatten, Maxime G, Gomez, F.J., Marchi Cappelletti, Rita, Alessandro Aliotta, Casini, Alessandro, Alessandro Casini, Marchi Cappelletti, R.   +26 more
core   +1 more source

Emicizumab [PDF]

Reactions Weekly, 2020
  +5 more sources